Dr. Issa discusses a real-world study¹ that demonstrated a reduced need for biologic treatments, among other AD treatments, in patients treated with topical ruxolitinib cream, and how this reduced utilization of biologics, combined with reductions in AD-related work absenteeism and productivity, has been shown to ameliorate economic impacts of AD on both the healthcare system and individual patients.²
References:
- Liu J, Desai K, Teng CC, et al. Atopic dermatitis treatments before and after initiation of ruxolitinib cream: analysis of a US payer claims database. Poster presented at AAD 2024.
- Bloudek L, Eichenfield LF, Silverberg JI, et al. Impact of ruxolitinib cream on work productivity and activity impairment and associated indirect costs in patients with atopic dermatitis: pooled results from 2 phase III studies. Am J Clin Dermatol. 2023;24(1):109-117.